Pfizer's Set to Make $131 Billion in COVID Sales in 2 Years. Is the Stock a Buy?

Pfizer's Set to Make $131 Billion in COVID Sales in 2 Years. Is the Stock a Buy?

None of them has been a bigger financial winner than Pfizer (NYSE: PFE). SVB Leerink analyst Geoffrey Porges estimates that Pfizer is set to make a stunning $131 billion in COVID-19 sales by the end of 2022. Let's first look at how Pfizer could make $160 billion from COVID-19 within the next two years.